Vol 6: Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and-or metastatic head and neck squamous cell carcinoma.Report as inadecuate



 Vol 6: Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and-or metastatic head and neck squamous cell carcinoma.


Vol 6: Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and-or metastatic head and neck squamous cell carcinoma. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 6: Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and-or metastatic head and neck squamous cell carcinoma.
This article is from OncoTargets and therapy, volume 6.AbstractBackground: Chronomodulated chemotherapy has emerged as a new therapy as a result of recent studies focusing on the biological clock. It has been demonstrated that combination chronomodulated chemotherapy of platinum-based drugs and 5-fluorouracil 5-Fu can significantly improve efficacy and reduce the incidence of adverse events in patients with metastatic colorectal cancer, as compared with conventional chemotherapy. However, the results may be different in different tumors. Recurrent and metastatic head and neck squamous cell carcinoma HNSCC is very difficult to treat, with an extremely unfavorable prognosis. So far, no report is available on chronomodulated chemotherapy for HNSCC. Methods: Retrospective analyses were made on 49 patients with local recurrent and-or metastatic HNSCC who underwent palliative treatments with paclitaxel, carboplatin, and 5-Fu. The patients were divided into a chronomodulated chemotherapy group 28 patients and a conventional chemotherapy group 21 patients according to their administration times. The two groups were compared for tumor objective response rate, overall survival OS, progression-free survival PFS, and the incidence of adverse events. Results: The tumor objective response rate and patients’ OS were significantly higher and longer in the chronomodulated chemotherapy group than in the conventional chemotherapy group 71.43% versus 42.86%, respectively, P



Author: Chen, Dan; Cheng, Jue; Yang, Kai; Ma, Yue; Yang, Fang

Source: https://archive.org/







Related documents